Urological cancer care pathways

development and use in the context of systematic reviews and clinical practice guidelines

Sara Jane Maclennan, Steven J Maclennan, Mari Imamura, Muhammad Imran Omar, Luke Vale, Thomas Lam, Pamela Royle, Justine Royle, Satchi Swami, Rob Pickard, Sam McClinton, T R Leyshon Griffiths, Philipp Dahm, James N'dow, UCAN Care Pathway Development Group

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background
Making healthcare treatment decisions is a complex process involving a broad stakeholder base including patients, their families, health professionals, clinical practice guideline developers and funders of healthcare.

Methods
This paper presents a review of a methodology for the development of urological cancer care pathways (UCAN care pathways), which reflects an appreciation of this broad stakeholder base. The methods section includes an overview of the steps in the development of the UCAN care pathways and engagement with clinical content experts and patient groups.

Results
The development process is outlined, the uses of the urological cancer care pathways discussed and the implications for clinical practice highlighted. The full set of UCAN care pathways is published in this paper. These include care pathways on localised prostate cancer, locally advanced prostate cancer, metastatic prostate cancer, hormone-resistant prostate cancer, localised renal cell cancer, advanced renal cell cancer, testicular cancer, penile cancer, muscle invasive and metastatic bladder cancer and non-muscle invasive bladder cancer.

Conclusion
The process provides a useful framework for improving urological cancer care through evidence synthesis, research prioritisation, stakeholder involvement and international collaboration. Although the focus of this work is urological cancers, the methodology can be applied to all aspects of urology and is transferable to other clinical specialties.

Original languageEnglish
Pages (from-to)291-301
Number of pages11
JournalWorld Journal of Urology
Volume29
Issue number3
Early online date4 Feb 2011
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Urologic Neoplasms
Practice Guidelines
Prostatic Neoplasms
Muscle Neoplasms
Renal Cell Carcinoma
Urinary Bladder Neoplasms
Penile Neoplasms
Delivery of Health Care
Professional Practice
Family Health
Testicular Neoplasms
Urology
Hormones
Research

Keywords

  • urological cancer
  • care pathways
  • systematic review
  • clinical practice guidelines

Cite this

Urological cancer care pathways : development and use in the context of systematic reviews and clinical practice guidelines. / Maclennan, Sara Jane; Maclennan, Steven J; Imamura, Mari; Omar, Muhammad Imran; Vale, Luke; Lam, Thomas; Royle, Pamela; Royle, Justine; Swami, Satchi; Pickard, Rob; McClinton, Sam; Griffiths, T R Leyshon; Dahm, Philipp; N'dow, James; UCAN Care Pathway Development Group.

In: World Journal of Urology, Vol. 29, No. 3, 06.2011, p. 291-301.

Research output: Contribution to journalArticle

Maclennan, SJ, Maclennan, SJ, Imamura, M, Omar, MI, Vale, L, Lam, T, Royle, P, Royle, J, Swami, S, Pickard, R, McClinton, S, Griffiths, TRL, Dahm, P, N'dow, J & UCAN Care Pathway Development Group 2011, 'Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines', World Journal of Urology, vol. 29, no. 3, pp. 291-301. https://doi.org/10.1007/s00345-011-0660-9
Maclennan, Sara Jane ; Maclennan, Steven J ; Imamura, Mari ; Omar, Muhammad Imran ; Vale, Luke ; Lam, Thomas ; Royle, Pamela ; Royle, Justine ; Swami, Satchi ; Pickard, Rob ; McClinton, Sam ; Griffiths, T R Leyshon ; Dahm, Philipp ; N'dow, James ; UCAN Care Pathway Development Group. / Urological cancer care pathways : development and use in the context of systematic reviews and clinical practice guidelines. In: World Journal of Urology. 2011 ; Vol. 29, No. 3. pp. 291-301.
@article{7760dc90f1df404ba42fbced9ad37432,
title = "Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines",
abstract = "Background Making healthcare treatment decisions is a complex process involving a broad stakeholder base including patients, their families, health professionals, clinical practice guideline developers and funders of healthcare. Methods This paper presents a review of a methodology for the development of urological cancer care pathways (UCAN care pathways), which reflects an appreciation of this broad stakeholder base. The methods section includes an overview of the steps in the development of the UCAN care pathways and engagement with clinical content experts and patient groups. Results The development process is outlined, the uses of the urological cancer care pathways discussed and the implications for clinical practice highlighted. The full set of UCAN care pathways is published in this paper. These include care pathways on localised prostate cancer, locally advanced prostate cancer, metastatic prostate cancer, hormone-resistant prostate cancer, localised renal cell cancer, advanced renal cell cancer, testicular cancer, penile cancer, muscle invasive and metastatic bladder cancer and non-muscle invasive bladder cancer. Conclusion The process provides a useful framework for improving urological cancer care through evidence synthesis, research prioritisation, stakeholder involvement and international collaboration. Although the focus of this work is urological cancers, the methodology can be applied to all aspects of urology and is transferable to other clinical specialties.",
keywords = "urological cancer, care pathways, systematic review, clinical practice guidelines",
author = "Maclennan, {Sara Jane} and Maclennan, {Steven J} and Mari Imamura and Omar, {Muhammad Imran} and Luke Vale and Thomas Lam and Pamela Royle and Justine Royle and Satchi Swami and Rob Pickard and Sam McClinton and Griffiths, {T R Leyshon} and Philipp Dahm and James N'dow and {UCAN Care Pathway Development Group}",
year = "2011",
month = "6",
doi = "10.1007/s00345-011-0660-9",
language = "English",
volume = "29",
pages = "291--301",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Urological cancer care pathways

T2 - development and use in the context of systematic reviews and clinical practice guidelines

AU - Maclennan, Sara Jane

AU - Maclennan, Steven J

AU - Imamura, Mari

AU - Omar, Muhammad Imran

AU - Vale, Luke

AU - Lam, Thomas

AU - Royle, Pamela

AU - Royle, Justine

AU - Swami, Satchi

AU - Pickard, Rob

AU - McClinton, Sam

AU - Griffiths, T R Leyshon

AU - Dahm, Philipp

AU - N'dow, James

AU - UCAN Care Pathway Development Group

PY - 2011/6

Y1 - 2011/6

N2 - Background Making healthcare treatment decisions is a complex process involving a broad stakeholder base including patients, their families, health professionals, clinical practice guideline developers and funders of healthcare. Methods This paper presents a review of a methodology for the development of urological cancer care pathways (UCAN care pathways), which reflects an appreciation of this broad stakeholder base. The methods section includes an overview of the steps in the development of the UCAN care pathways and engagement with clinical content experts and patient groups. Results The development process is outlined, the uses of the urological cancer care pathways discussed and the implications for clinical practice highlighted. The full set of UCAN care pathways is published in this paper. These include care pathways on localised prostate cancer, locally advanced prostate cancer, metastatic prostate cancer, hormone-resistant prostate cancer, localised renal cell cancer, advanced renal cell cancer, testicular cancer, penile cancer, muscle invasive and metastatic bladder cancer and non-muscle invasive bladder cancer. Conclusion The process provides a useful framework for improving urological cancer care through evidence synthesis, research prioritisation, stakeholder involvement and international collaboration. Although the focus of this work is urological cancers, the methodology can be applied to all aspects of urology and is transferable to other clinical specialties.

AB - Background Making healthcare treatment decisions is a complex process involving a broad stakeholder base including patients, their families, health professionals, clinical practice guideline developers and funders of healthcare. Methods This paper presents a review of a methodology for the development of urological cancer care pathways (UCAN care pathways), which reflects an appreciation of this broad stakeholder base. The methods section includes an overview of the steps in the development of the UCAN care pathways and engagement with clinical content experts and patient groups. Results The development process is outlined, the uses of the urological cancer care pathways discussed and the implications for clinical practice highlighted. The full set of UCAN care pathways is published in this paper. These include care pathways on localised prostate cancer, locally advanced prostate cancer, metastatic prostate cancer, hormone-resistant prostate cancer, localised renal cell cancer, advanced renal cell cancer, testicular cancer, penile cancer, muscle invasive and metastatic bladder cancer and non-muscle invasive bladder cancer. Conclusion The process provides a useful framework for improving urological cancer care through evidence synthesis, research prioritisation, stakeholder involvement and international collaboration. Although the focus of this work is urological cancers, the methodology can be applied to all aspects of urology and is transferable to other clinical specialties.

KW - urological cancer

KW - care pathways

KW - systematic review

KW - clinical practice guidelines

U2 - 10.1007/s00345-011-0660-9

DO - 10.1007/s00345-011-0660-9

M3 - Article

VL - 29

SP - 291

EP - 301

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -